Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta.
We describe a patient with osteogenesis imperfecta type 1A who was treated with growth hormone for 9 years. The treatment resulted in a marked improvement in growth velocity, but four fractures occurred during the pubertal period.
Noda
Hiromasa
H
Department of Pediatrics, Funabashi Central Hospital, Chiba, Japan.
Onishi
Hisashi
H
Saitoh
Kimiyuki
K
Nakajima
Hironori
H
D000293:Adolescent; D001827:Body Height; D001842:Bone and Bones / Q000293:injuries*; D050723:Fractures, Bone / Q000209:etiology*; D019382:Human Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010013:Osteogenesis Imperfecta / Q000150:complications* / Q000188:drug therapy*; D011627:Puberty; D012307:Risk Factors
D019382:Human Growth Hormone